Cargando…

Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease

Comorbid Lewy body pathology is very common in Alzheimer’s disease and may confound clinical trial design, yet there is no in vivo test to identify patients with this. Tissue (and/or radioligand imaging) studies have shown cardiac sympathetic denervation in Parkinson’s disease and dementia with Lewy...

Descripción completa

Detalles Bibliográficos
Autores principales: Serrano, Geidy E, Shprecher, David, Callan, Michael, Cutler, Brett, Glass, Michael, Zhang, Nan, Walker, Jessica, Intorcia, Anthony, Adler, Charles H, Shill, Holly A, Driver-Dunckley, Erika, Mehta, Shyamal H, Belden, Christine M, Zamrini, Edward, Sue, Lucia I, Vargas, Daisy, Beach, Thomas G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008146/
https://www.ncbi.nlm.nih.gov/pubmed/32064463
http://dx.doi.org/10.1093/braincomms/fcaa004
_version_ 1783495425625423872
author Serrano, Geidy E
Shprecher, David
Callan, Michael
Cutler, Brett
Glass, Michael
Zhang, Nan
Walker, Jessica
Intorcia, Anthony
Adler, Charles H
Shill, Holly A
Driver-Dunckley, Erika
Mehta, Shyamal H
Belden, Christine M
Zamrini, Edward
Sue, Lucia I
Vargas, Daisy
Beach, Thomas G
author_facet Serrano, Geidy E
Shprecher, David
Callan, Michael
Cutler, Brett
Glass, Michael
Zhang, Nan
Walker, Jessica
Intorcia, Anthony
Adler, Charles H
Shill, Holly A
Driver-Dunckley, Erika
Mehta, Shyamal H
Belden, Christine M
Zamrini, Edward
Sue, Lucia I
Vargas, Daisy
Beach, Thomas G
author_sort Serrano, Geidy E
collection PubMed
description Comorbid Lewy body pathology is very common in Alzheimer’s disease and may confound clinical trial design, yet there is no in vivo test to identify patients with this. Tissue (and/or radioligand imaging) studies have shown cardiac sympathetic denervation in Parkinson’s disease and dementia with Lewy bodies, but this has not been explored in Alzheimer’s subjects with Lewy bodies not meeting dementia with Lewy bodies clinicopathological criteria. To determine if Alzheimer’s disease with Lewy bodies subjects show sympathetic cardiac denervation, we analysed epicardial and myocardial tissue from autopsy-confirmed cases using tyrosine hydroxylase and neurofilament immunostaining. Comparison of tyrosine hydroxylase fibre density in 19 subjects with Alzheimer’s disease/dementia with Lewy bodies, 20 Alzheimer’s disease with Lewy bodies, 12 Alzheimer’s disease subjects without Lewy body disease, 19 Parkinson’s disease, 30 incidental Lewy body disease and 22 cognitively normal without Alzheimer’s disease or Lewy body disease indicated a significant group difference (P < 0.01; Kruskal–Wallis analysis of variance) and subsequent pair-wise Mann–Whitney U tests showed that Parkinson’s disease (P < 0.05) and Alzheimer’s disease/dementia with Lewy bodies (P < 0.01) subjects, but not Alzheimer’s disease with Lewy bodies subjects, had significantly reduced tyrosine hydroxylase fibre density as compared with cognitively normal. Both Parkinson’s disease and Alzheimer’s disease/dementia with Lewy bodies subjects also showed significant epicardial losses of neurofilament protein-immunoreactive nerve fibre densities within the fibre bundles as compared with cognitively normal subjects (P < 0.01) and both groups showed high pathologic alpha-synuclein densities (P < 0.0001). Cardiac alpha-synuclein densities correlated significantly with brain alpha-synuclein (P < 0.001), while cardiac tyrosine hydroxylase and neurofilament immunoreactive nerve fibre densities were negatively correlated with the densities of both brain and cardiac alpha-synuclein, as well as Unified Parkinson’s Disease Rating Scale scores (P < 0.05). The clear separation of Alzheimer’s disease/dementia with Lewy bodies subjects from Alzheimer’s disease and cognitively normal, based on cardiac tyrosine hydroxylase fibre density, is the first report of a statistically significant difference between these groups. Our data do not show significant sympathetic cardiac denervation in Alzheimer’s disease with Lewy bodies, but strongly confirm that cardiac nuclear imaging with a noradrenergic radioligand is worthy of further study as a potential means to separate Alzheimer’s disease from Alzheimer’s disease/dementia with Lewy bodies during life.
format Online
Article
Text
id pubmed-7008146
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-70081462020-02-13 Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease Serrano, Geidy E Shprecher, David Callan, Michael Cutler, Brett Glass, Michael Zhang, Nan Walker, Jessica Intorcia, Anthony Adler, Charles H Shill, Holly A Driver-Dunckley, Erika Mehta, Shyamal H Belden, Christine M Zamrini, Edward Sue, Lucia I Vargas, Daisy Beach, Thomas G Brain Commun Original Article Comorbid Lewy body pathology is very common in Alzheimer’s disease and may confound clinical trial design, yet there is no in vivo test to identify patients with this. Tissue (and/or radioligand imaging) studies have shown cardiac sympathetic denervation in Parkinson’s disease and dementia with Lewy bodies, but this has not been explored in Alzheimer’s subjects with Lewy bodies not meeting dementia with Lewy bodies clinicopathological criteria. To determine if Alzheimer’s disease with Lewy bodies subjects show sympathetic cardiac denervation, we analysed epicardial and myocardial tissue from autopsy-confirmed cases using tyrosine hydroxylase and neurofilament immunostaining. Comparison of tyrosine hydroxylase fibre density in 19 subjects with Alzheimer’s disease/dementia with Lewy bodies, 20 Alzheimer’s disease with Lewy bodies, 12 Alzheimer’s disease subjects without Lewy body disease, 19 Parkinson’s disease, 30 incidental Lewy body disease and 22 cognitively normal without Alzheimer’s disease or Lewy body disease indicated a significant group difference (P < 0.01; Kruskal–Wallis analysis of variance) and subsequent pair-wise Mann–Whitney U tests showed that Parkinson’s disease (P < 0.05) and Alzheimer’s disease/dementia with Lewy bodies (P < 0.01) subjects, but not Alzheimer’s disease with Lewy bodies subjects, had significantly reduced tyrosine hydroxylase fibre density as compared with cognitively normal. Both Parkinson’s disease and Alzheimer’s disease/dementia with Lewy bodies subjects also showed significant epicardial losses of neurofilament protein-immunoreactive nerve fibre densities within the fibre bundles as compared with cognitively normal subjects (P < 0.01) and both groups showed high pathologic alpha-synuclein densities (P < 0.0001). Cardiac alpha-synuclein densities correlated significantly with brain alpha-synuclein (P < 0.001), while cardiac tyrosine hydroxylase and neurofilament immunoreactive nerve fibre densities were negatively correlated with the densities of both brain and cardiac alpha-synuclein, as well as Unified Parkinson’s Disease Rating Scale scores (P < 0.05). The clear separation of Alzheimer’s disease/dementia with Lewy bodies subjects from Alzheimer’s disease and cognitively normal, based on cardiac tyrosine hydroxylase fibre density, is the first report of a statistically significant difference between these groups. Our data do not show significant sympathetic cardiac denervation in Alzheimer’s disease with Lewy bodies, but strongly confirm that cardiac nuclear imaging with a noradrenergic radioligand is worthy of further study as a potential means to separate Alzheimer’s disease from Alzheimer’s disease/dementia with Lewy bodies during life. Oxford University Press 2020-01-28 /pmc/articles/PMC7008146/ /pubmed/32064463 http://dx.doi.org/10.1093/braincomms/fcaa004 Text en © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Serrano, Geidy E
Shprecher, David
Callan, Michael
Cutler, Brett
Glass, Michael
Zhang, Nan
Walker, Jessica
Intorcia, Anthony
Adler, Charles H
Shill, Holly A
Driver-Dunckley, Erika
Mehta, Shyamal H
Belden, Christine M
Zamrini, Edward
Sue, Lucia I
Vargas, Daisy
Beach, Thomas G
Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease
title Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease
title_full Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease
title_fullStr Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease
title_full_unstemmed Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease
title_short Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease
title_sort cardiac sympathetic denervation and synucleinopathy in alzheimer’s disease with brain lewy body disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008146/
https://www.ncbi.nlm.nih.gov/pubmed/32064463
http://dx.doi.org/10.1093/braincomms/fcaa004
work_keys_str_mv AT serranogeidye cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT shprecherdavid cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT callanmichael cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT cutlerbrett cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT glassmichael cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT zhangnan cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT walkerjessica cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT intorciaanthony cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT adlercharlesh cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT shillhollya cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT driverdunckleyerika cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT mehtashyamalh cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT beldenchristinem cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT zamriniedward cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT sueluciai cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT vargasdaisy cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease
AT beachthomasg cardiacsympatheticdenervationandsynucleinopathyinalzheimersdiseasewithbrainlewybodydisease